La vendita allo scoperto per Aurinia Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Aurinia Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Aurinia Pharmaceuticals (NASDAQ:AUPH) Azioni, Report sulle vendite allo scoperto

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals Inc

Kevin O'Leary isn't shy with opinions. But during a debate last week <a href="https://youtu.be/No9njUCa7fs?si=K-enJc2_i4O4X3g0">hosted on Anthony Scaramucci's YouTube channel</a>, the "Shark Tank" star revealed something unexpected: a brutal but respectful comparison between Steve Jobs and Elon Musk — and why he believes there's never been anyone quite like Musk.
The debate, posted last week as part of Scaramucci's series "Open Book," featured a wide-ranging conversation covering President Donald Trump, crypto, Canada, and whether investors should side with Sam Altman or Musk. But when asked about the two AI titans, O'Leary didn't go with either. Instead, he took a hard left — <a href="https://www.benzinga.com/personal-finance/25/04/44780772/bill-gates-said-its-a-gross-oversimplification-to-compare-elon-musk-to-genius-steve-jobs-you-wouldnt-walk-into-a-room-and-confu">straight into Apple territory</a>.
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
"I worked for Steve Jobs," O'Leary said, after noting that his son Trevor works for Musk at Tesla and adding, "we love Elon." He described Jobs as "about 80% signal, 10% noise… not easy to work with, very unpopular, really nasty guy, but he really got it.
Then came the pivot.
"Elon has no noise. He's 100% signal," O'Leary continued. "He wastes zero time in his day. He can't. He'll <a href="https://www.benzinga.com/personal-finance/25/03/44346635/kevin-o-leary-says-elon-musk-will-walk-away-mid-conversation-if-he-gets-bored-he-doesnt-give-a-sht-ive-never-met-anybody-like-him">walk away from a conversation</a> with you if he's wasting time. He has zero time to waste. There's never been a man like him."
The comparison wasn't meant as an insult to Jobs — far from it. O'Leary has long acknowledged how difficult Jobs was behind closed doors, but he's also made it clear that he admired him deeply.
Trending: The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a>
In a <a href="https://www.facebook.com/share/r/1EgoCLXoSN/?mibextid=wwXIfr">Facebook post from last year</a>, O'Leary reflected on working for the Apple co-founder. "What was it like working for Steve Jobs? It was BRUTAL! He was NOT a nice guy," he wrote. Attached was a clip of O'Leary candidly recalling how Jobs would "walk into a room and absolutely berate everybody in there." Despite that, O'Leary wrote, "I admired him for his steel vision and getting where he needed to go. He didn't let people get in the way."
That track record — brilliance bordering on brutality — has been echoed in stories from those who knew Jobs personally. In her 2018 memoir "Small Fry," daughter <a href="https://www.nytimes.com/2018/08/23/books/steve-jobs-lisa-brennan-jobs-small-fry.html">Lisa Brennan-Jobs shared her account of growing up with him</a>, including claims that he refused to install heat in her bedroom and once told her she would receive no inheritance.
The takeaway, at least for O'Leary, seems to be that greatness often comes with difficult personalities — but in Musk's case, the delivery is different. Jobs may have berated people to get results, but Musk, he implies, simply doesn't waste time on anything — or anyone — that slows him down.
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
Still, it's Musk who now holds O'Leary's admiration — and not just because of his son's connection to Tesla. O'Leary pointed to Musk's relentless work ethic, efficiency, and boldness as traits that separate him from everyone else. "Thank goodness he's doing Doge right now," O'Leary said, half-jokingly. "He's going to save a sh&#x2A;tload of money. That's great."
As usual, Mr. Wonderful didn't hold back — and in doing so, he gave a brutally honest glimpse into the world of billionaires who play by a different set of rules, whether they're launching rockets or yelling in conference rooms.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Kevin O'Leary Says Steve Jobs Was 'Very Unpopular' And A 'Really Nasty Guy' — But Elon Musk? 'There's Never Been A Man Like Him'

ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) has outperformed the market over the past 10 years by 18.86% on an annualized basis producing an average annual return of 29.6%. Currently, ServiceNow has a market capitalization of $214.26 billion. 
Buying $1000 In NOW: If an investor had bought $1000 of NOW stock 10 years ago, it would be worth $13,309.08 today based on a price of $1035.18 for NOW at the time of writing.
<h3>ServiceNow's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747341011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $1000 Invested In ServiceNow 10 Years Ago Would Be Worth Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 13.87% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 12.00% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 8.67% at $0.38</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 7.81% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 7.30% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 7.14% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 6.87% at $7.00</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 5.38% at $0.44</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 4.73% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 4.17% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 4.00% at $0.88</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed up 3.91% at $4.66</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 3.70% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed up 3.70% at $61.08</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 3.48% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 3.23% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 3.07% at $5.71</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 34.29% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 33.33% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 15.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 12.27% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 10.45% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 10.00% at $0.93</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 8.63% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 7.35% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 5.71% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed down 5.03% at $1.56</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 4.25% at $1.34</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 4.13% at $0.24</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNTMF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

FFNTF

GNLN

GTBIF

ITHUF

KAYS

LMLLF

LVRLF

MGWFF

MRMD

NWVCF

OILFF

RMHB

SOLCF

TCNNF

TGIFF

UGRO

ZDPY

Marijuana Stock Movers For May 15, 2025

Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.20) by 35 percent. This is a 48 percent increase over losses of $(0.25) per share from the same period last year.

Earnings

Earnings Beats

RVPH

Reviva Pharmaceuticals Q1 EPS $(0.13) Beats $(0.20) Estimate

Exane BNP Paribas analyst Andrew Buscaglia initiates coverage on Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) with a Outperform rating and announces Price Target of $380.

Price Target

Initiation

Analyst Ratings

Exane BNP Paribas Initiates Coverage On Eaton Corp with Outperform Rating, Announces Price Target of $380

Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) reported quarterly earnings of $0.03 per share. This is a 100.2 percent increase over losses of $(14.93) per share from the same period last year. The company reported $25.50 million in sales this quarter. This is a 93.02 percent increase over sales of $13.21 million the same period last year.

SOAR

Volato Group Q1 EPS $0.03 Up From $(14.93) YoY, Sales $25.50M Up From $13.21M YoY

WIIM

GLOB

Globant shares are trading lower after the company reported worse-than-expected Q1 financial results, issued Q2 guidance below estimates, and cut its FY25 guidance.

Third Point Adds Stake In AT&T Of 3.775M Shares

– Late-Breaking Data from the Phase 3 ASCENT-04/KEYNOTE-D19 Study Evaluating Trodelvy&#xAE; plus Keytruda&#xAE; in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer –

Biotech

Events

General

GILD

Gilead And Kite To Present Data In 1L Metastatic Triple-Negative Breast Cancer, Updated Results In Multiple Myeloma And Early Data From  Investigational CAR T-Cell Therapy Targeting Brain Cancer At 2025 ASCO And EHA

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) shares fell 2.2% to $645.07 on Thursday afternoon following a Wall Street Journal <a href="https://www.wsj.com/tech/ai/meta-is-delaying-the-rollout-of-its-flagship-ai-model-f4b105f7">report</a> that revealed delays in the company's release of its next-generation AI model, codenamed Behemoth.
The model, once expected as early as April, has now been pushed to fall or later, according to people familiar with the matter, the Wall Street Journal said.
What To Know: Engineers have <a href="https://www.wsj.com/tech/ai/meta-is-delaying-the-rollout-of-its-flagship-ai-model-f4b105f7">reportedly</a> struggled to achieve meaningful improvements over previous versions, leading to internal debate over whether Behemoth is ready for public release. 
Although Meta has <a href="https://www.benzinga.com/content/44983119/meta-releases-llama-4-it-could-help-drive-big-growth-long-term">promoted</a> Behemoth as surpassing OpenAI and Alphabet (Google) models in some benchmarks, training difficulties have stunted progress, the Wall Street Journal noted.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/05/45447252/wall-street-wavers-as-unh-tumbles-foot-locker-soars-whats-driving-markets-thursday">Wall Street Wavers As UNH Tumbles, Foot Locker Soars: What&#8217;s Driving Markets Thursday?</a>
The delay comes amid mounting pressure on <a href="https://www.benzinga.com/markets/25/04/44661561/mark-zuckerbergs-meta-unveils-latest-llama-4-ai-models-to-challenge-openais-chatgpt-4-and-googles-gemini">Meta's AI ambitions</a>, which are backed by a projected $72 billion in capital expenditures this year.
Internal frustrations have surfaced, with some executives blaming the <a href="https://www.benzinga.com/tech/25/04/45075691/meta-launches-ai-app-to-compete-with-chatgpt-gemini-grok">Llama 4</a> team for the setbacks and considering management changes, the Wall Street Journal noted.
The Wall Street Journal said Meta on Thursday declined to comment on the timeline or internal issues. The delays echo broader industry slowdowns, with companies such as OpenAI and <a href="https://www.benzinga.com/topic/anthropic">Anthropic</a> also facing lags in rolling out advanced models.
Read Also: <a href="https://www.benzinga.com/news/25/05/45445582/plug-power-stock-hits-a-new-52-week-low-whats-going-on">Plug Power Stock Hits A New 52-Week Low: What&#8217;s Going On?</a>
<h1 class="wp-block-heading">How To Buy META Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, Meta Platforms is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, META has a 52-week high of $740.89 and a 52-week low of $442.65.
Photo: Courtesy of Meta Platforms

Tech

Meta Platforms Stock Dips On AI Rollout Delay Amid Internal Turmoil: Report

CRWV

Nvidia Adds Stake In CoreWeave Of ~24.18M Shares

Hedge Funds

AMZN

13F Shows Third Point Cut Stake In Amazon.com Inc To 2.35M Shares (From 3.45M)

Management

LODE

Comstock Appoints Judd B. Merrill As Chief Financial Officer, Effective May 19, 2025

Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.97) by 53.61 percent. This is a 40 percent increase over losses of $(0.75) per share from the same period last year.

BCLI

Brainstorm Cell Q1 EPS $(0.45) Beats $(0.97) Estimate

TSLA

Third Point Sells Stakes In Tesla, Meta

Exane BNP Paribas analyst Moses Sutton downgrades Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) from Neutral to Underperform and lowers the price target from $4.5 to $4.

Downgrades

SHLS

Exane BNP Paribas Downgrades Shoals Technologies Gr to Underperform, Lowers Price Target to $4

Buybacks

LCII

LCI Industries Authorized $300M Stock Repurchase Program

Safe Pro Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) reported quarterly losses of $(0.27) per share. This is a 107.69 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $184.80 thousand in sales this quarter. This is a 39.93 percent decrease over sales of $307.65 thousand the same period last year.

SPAI

Safe Pro Group Q4 EPS $(0.27) Down From $(0.13) YoY, Sales $184.80K Down From $307.65K YoY

PINS

13F Shows Third Point Took New Stake In Pinterest Inc Of 1M Shares

JBLU

Carl Icahn Raises Stake It JetBlue Airways From ~17.27M Shares To ~33.62M Shares

Press Releases

Aurinia to Participate in Jefferies London Healthcare Conference

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

Comments

Aurinia Pharmaceuticals

Vendite allo scoperto

Aurinia Pharmaceuticals (NASDAQ:AUPH) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO